• kākoʻo_banner

ʻOihana Antibody Monoclonal

ʻO ka antibody monoclonal, i hana ʻia e kahi clone cell B hoʻokahi, he homogeneity kiʻekiʻe e kuhikuhi ana i kahi epitope antigen kikoʻī.He nui nā pōmaikaʻi o ka antibody monoclonal, me ka maʻemaʻe kiʻekiʻe, ka naʻau, a me ka kikoʻī.Hoʻokumu ʻia nā Hybridoma ma o ka hui ʻana o nā lymphocytes B e hoʻopuka ana i kekahi mau antibodies kikoʻī, me nā cell myeloma lōʻihi.Hoʻohana ʻo Bioantibody i kahi ʻenehana fusion kiʻekiʻe i ʻoi aku ka maikaʻi o 20 mau manawa ma mua o nā ʻano fusion maʻamau.Hoʻohui ʻia, hoʻohana ia i ka ʻenehana screening microarray protein e ʻike ai i nā antibodies monoclonal e hōʻike ana i ka kikoʻī kiʻekiʻe, pili, a me ka pono hana e kūʻē i nā epitopes kikoʻī.

Kaʻina Hana Hana

杂交瘤

Nā mea lawelawe

Nā mea lawelawe Nā mea hoʻokolohua Lead Time(Week)
Hoʻomākaukau antigen
1. Hāʻawi ka mea kūʻai aku i ka antigen2. Hoʻomākaukau ka bioantibody i ka antigen /
Kaʻiole ʻiole ʻO ka pale ʻana o ka ʻiole BALB/c, ka hōʻiliʻili serum a me ka nānā ʻana ELISA 4
ʻO ka hui pū ʻana a me ka nānā ʻana ʻO ka hui ʻana o nā splenocytes ʻiole a me nā cell myeloma, ka nānā ʻana i ka HAT 2
Hoʻokumu laina kelepona paʻa Hoʻokaʻawale ʻia nā clones maikaʻi i hoʻopaʻa ʻia 3
ʻIke ʻana i ka antibody isotype Ka ʻike ʻana i nā ʻano subtype laina kelepona 1
ʻO ka hoʻoulu ʻana i ka pānaʻi liʻiliʻi ʻO ka hoʻoulu ʻana i ka serum-free 2
ʻO ka incubation nui a me ka hoʻomaʻemaʻe 200mL serum-free incubation a hoʻomaʻemaʻe 1

Pono lawelawe

ʻO ka manawa hoʻololi pōkole

ʻO Bioantibody Self-developed Technology Platform

Hoʻonui ka ʻenehana Hybridoma Fusion High-efficiency i ka Fusion Efficiency By20 manawa
0331(2)(1)

Kaʻina Kauoha

E ʻoluʻoluhoʻoiho i ka palapala kauohaa hoʻopiha e like me ka makemake a hoʻouna i leka uila iservice@bkbio.com.cn

025-58501988